Business Context and Reporting Period
Company: Axe Compute Inc. (AGPU)
Filing Type: Form 8-K (Current Report)
Date of Report: September 11, 2026
Event: Entry into a Material Definitive Agreement and Completion of Asset Disposition.
On September 11, 2026, Axe Compute Inc. sold all issued and outstanding shares of its wholly-owned subsidiary, Helomics Corporation, to DataMeds AI, Inc. (NASDAQ: MEDS). This transaction marks the completion of Axe Compute's strategic transition to a pure-play neocloud GPU-as-a-Service company, divesting its final operating business from its former identity as Predictive Oncology Inc.
Key Financial Metrics and Transaction Terms
The filing details the consideration received for the sale of Helomics but does not provide standalone revenue, profit, cash flow, or margin data for the reporting period.
- Total Consideration:
- Equity: 636,328 shares of DataMeds common stock (representing 19.99% of DataMeds' outstanding shares pre-closing).
- Debt Instrument: A convertible promissory note with a principal amount of $1,363,672.
- Convertible Note Terms: Conversion price of $1.00 per share.
- Liquidity Impact: The Company assumed the remaining base rent obligations for two Helomics leases in Pittsburgh, PA, through their expiration. Operating expenses, taxes, and utilities are the responsibility of DataMeds post-closing.
Material Changes and Strategic Shift
The primary material change is the divestiture of Helomics, which was the last remaining legacy business unit. This action finalizes the company's pivot away from its previous oncology focus to a specialized GPU-as-a-Service model. The transaction closed simultaneously with the execution of the agreement on September 11, 2026.
Guidance, Risks, and Contingencies
- Lock-Up Period: The Consideration Shares and any shares issuable upon conversion of the Convertible Note are subject to a 12-month lock-up period from the closing date. Transfer is restricted except to affiliates or with DataMeds' prior written consent.
- Non-Compete: Axe Compute is subject to a covenant not to compete with the business of Helomics following the closing.
- Registration Rights: The agreement grants Axe Compute certain registration rights regarding the Consideration Shares and converted shares.
- Financial Statements: This 8-K filing does not contain audited financial statements or forward-looking guidance regarding future revenue or earnings.
Investor Verification Checklist
- Verify the current market value of the 636,328 DataMeds shares received to assess the total transaction value.
- Review the terms of the $1,363,672 convertible note, specifically the conversion mechanics and interest provisions (if any).
- Confirm the remaining duration and total cost of the base rent obligations Axe Compute assumed for the Pittsburgh leases.
- Monitor the 12-month lock-up expiration date for potential future liquidity events regarding the DataMeds equity.
- Examine the full text of the Stock Purchase Agreement (Exhibit 2.1) for specific indemnification and warranty details.